FDA panel to review denosumab

Amgen Inc. (NASDAQ:AMGN) said FDA's Reproductive Health Drugs Advisory Committee will meet on Aug. 13 to discuss a BLA for denosumab to treat and prevent postmenopausal osteoporosis and to treat and p...